INIBIOLP   05426
INSTITUTO DE INVESTIGACIONES BIOQUIMICAS DE LA PLATA "PROF. DR. RODOLFO R. BRENNER"
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Development and characterization of solid lipid nanoparticles as efficient carriers for lipidic drugs against lung adenocarcinoma tumoral cells
Autor/es:
RODENAK-KLADNIEW B; CASTRO GR; GARCIA M; GARCIA M; ISLAN GA; DURAN N; ISLAN GA; DURAN N; RODENAK-KLADNIEW B; CASTRO GR
Lugar:
Rosario
Reunión:
Congreso; 4ta Reunion Internacional de Ciencias Farmaceuticas; 2016
Resumen:
Solid lipid nanoparticles (SLN) with different compositions have been developed for an efficient encapsulation of lipophilic compounds with biological activities in order to improve their bioavailability in physiological mediums. Linalool (LN) is a monoterpene found in essential oils of plants showing antiproliferative activity in cancer cells and proposed as model drug. SLNs composed of lipids with melting points from 41ºC to 53ºC were prepared by ultrasonication method in presence of Pluronic®F68 as surfactant. The LN encapsulation percentages in SLNs were in the range of 80-90% for the tested formulations and exhibited in vitro LN controlled release profiles for 72 h. The nanoparticle´s size, morphology and distribution were determined by dynamic light scattering (DLS) combined with transmission electron microscopy (TEM). SLNs displayed spherical shape and mean diameters in the range of 90-130 nm with narrow size dispersion (PDI) lower than 0.2 and Z-potentials around -4.0 mV. The loaded nanoparticles were extensively characterized by FTIR, XRD, DSC and TGA and results indicated the presence of weak interactions between the components that change the thermal and structural properties of SLNs. The formulations, and particularly SLN composed of myristyl myristate as lipid matrix, showed in vitro antiproliferative effects against lung adenocarcinoma (A549) cell lines in a dose/time manner, enhancing the citotoxicity compared with free LN. In addition, the cellular uptake of SLN was observed by labeling the SLNs with a fluorescent probe, indicating the ability of nanoparticles to enter into tumoral cells and intracellularly deliver the cargo molecules.